Moreover, unlike AR antagonist agents whose efficacy can be attenuated by high androgen levels, ITRI-90 by degrading the AR proteins, is sufficient to inhibit tumor growth even in high androgen environment, which is present in CRPC tumors resulting from intracrine steroidogenesis.63 The gene discussed is AR; the disease is neoplasm.